Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 5/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756755 | 0.91 | PTK2 (0.48) | FGFR4IKBKBCDK5CDK5R1PTK2 | |
| SCHEMBL13756756 | 0.88 | PTGS2 (0.48) | FGFR4CDK5CDK5R1PTK2JAK2 | |
| SCHEMBL13756693 | 0.88 | PTGS2 (0.47) | FGFR4IKBKBCDK5CDK5R1PTK2 | |
| SCHEMBL13756834 | 0.86 | CDK2 (0.43) | CDK5CDK5R1PTK2JAK2JAK3 | |
| SCHEMBL13756691 | 0.86 | AURKA (0.54) | FGFR4PTK2JAK2JAK3FLT3 | |
| SCHEMBL13756831 | 0.86 | LRRK2 (0.49) | PTK2EGFRMAPK1MAPT | |
| SCHEMBL13756846 | 0.85 | CDK2 (0.44) | IKBKBCDK5CDK5R1PTK2JAK2 | |
| SCHEMBL13756828 | 0.83 | TTK (0.53) | PTK2JAK2JAK3EGFR | |
| SCHEMBL13756752 | 0.81 | BRD4 (0.49) | MAPTPTGS2 | |
| SCHEMBL13756800 | 0.79 | CDK2 (0.46) | CDK5CDK5R1PTK2JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | FGFR4 660/4885IKBKB 287/4885CDK5 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.